Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-256 and Divozilimab in Systemic Lupus Erythematosus
NCT07136389Phase 1Recruiting
- Sponsor
- BIOCAD
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCD-256 in systemic lupus erythematosus (SLE) (9 arms), sponsored by BIOCAD. Primary endpoints: Proportion of subjects with adverse events at 85 days, Proportion of subjects with serious adverse events at 85 days and 4 more. Started Mar 2025; status: recruiting.
02
Drugs
BCD-256
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07136389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136389.